Monday 1 July 2024

The Pharma Letter Podcast — Episode 12 — Mastering the microbiome

Biotechnology
Simon Wentworth
9 March 2022
episode12-b

More on this story...

Biotechnology
Takeda leads Big Pharma in microbiome-targeting treatments
17 August 2021
Biotechnology
Third clinical program bought by AI-based microbiome specialist
27 April 2022
Biotechnology
Takeda pulls out of deal with Finch on microbiome candidates for IBD
26 August 2022
Biotechnology
MaaT Pharma partners with Skyepharma on microbiome production
9 February 2022


Related Company News

Seres severs ties with Vowst to focus on future
EnteroBiotix strengthens its executive team
Former Merck KGaA heavyweight joins EnteroBiotix as executive chairman
FDA nod for new microbiome-based therapeutic VOWST production at Recipharm site
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze